Everything below concerns HGF/c-Met. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
In 1998, Firehouse Subs surpassed 10 locations, and later that year opened the first location outside of Florida. In 2000, the founders decided to take a different approach, using consultants to plan franchise growth. They were able to set up financing for potential franchisees. The second wave of franchising began in 2001. In 2011, Firehouse Subs opened its first franchises in the U.S. territory of Puerto Rico, via local franchisee Caribbean Restaurants. By 2012 the company reached 500 locations, ending the year with nearly 600. In July 2016, Firehouse Subs opened its 1,000th location. In 2015, Firehouse Subs opened its first locations in Canada, with its first location opening in Oshawa, Ontario in October with franchisee OnFire Restaurant Group. Currently, the group operates 50 Canadian restaurants, with plans to open a total of 90 in Ontario alone. The chain also launched a loyalty program. In June 2017, Firehouse Subs opened its first airport location at Jacksonville International. In December 2017, the brand's second airport location opened at Orlando International. In April 2018, the chain opened its first on-campus location at Western New England University. In 2020 the chain opened a location at Jacksonville's Baptist Medical Center. On November 15, 2021, Burger King parent Restaurant Brands International announced that it would acquire Firehouse Subs for $1 billion. The acquisition was completed on December 15, 2021. On June 22, 2023, Firehouse Subs opened its first location outside North America in Zurich, Switzerland.
Strength: maximum amount of stress that material can withstand while staying in the elastic (reversible) deformation regime; Geometric stiffness: a global characteristic of the body that depends on its shape, and not only on the local properties of the material; for instance, an I-beam has a higher bending stiffness than a rod of the same material for a given mass per length; Hardness: relative resistance of the material's surface to penetration by a harder body; Toughness: amount of energy that a material can absorb before fracture. The point E is the elastic limit or the yield point of the material within which the stress is proportional to strain and the material regains its original shape after removal of the external force.
Old Etonian undergraduate Ed Haddon (who had rowed for Isis in 1992) was dropped in favour of German Philipp Schuller. Schuller had arrived at Oxford just two months earlier, but rejected suggestions that his late inclusion was symptomatic of the recent influx of "professionals" to the race. Of his selection, he noted: "You can't have one of the most respected races in the world and then limit it to English people between the ages of 19 and 21 ... on the day we went for whoever would make the boat go fastest. It was done entirely on merit." Schuller's compatriot and opponent Dirk Bangert had struggled with the move to cleavers, finding it difficult to adjust his timing: "I nearly didn't make it. I couldn't get this rhythm until about three weeks ago and was not sure of my place." Oxford's finishing coach was Mike Spracklen who had assisted the Dark Blues in five victorious races, while Cambridge had New Zealander Harry Mahon in charge for the first time, assisted by John Wilson (who had helped coach Oxford to a win in the 1991 race), and Sean Bowden, who was subsequently credited with "being half of the team which first turned Cambridge round". Oxford's head coach Patrick Sweeney noted: "If [Cambridge] get away, they will be hard to beat. If they don't, they're dead meat."
It is a pliable, mesh-like tissue with a fluid matrix and functions to cushion and protect body organs. Fibroblasts are widely dispersed in this tissue; they are irregular branching cells that secrete strong fibrous proteins and proteoglycans as an extracellular matrix. The cells of this type of tissue are generally connected by a gelatinous substance known as ground substance primarily made up of collagenous and elastic fibers.
vacuum flask Also Dewar flask or thermos. A storage vessel consisting of two flasks or other containers, placed one within the other and joined at the neck, and a space in between that is partially evacuated of air, creating a near-vacuum that significantly reduces the transfer of heat between the vessel's interior and its ambient environment. Vacuum flasks can greatly lengthen the time over which their contents remain warmer or cooler than the ambient environment.
Sources: en.wikipedia.org
==== Legislature ==== The U.S. Congress is a bicameral legislature made up of the Senate and the House of Representatives. The Senate has 100 members—two residents from each state and elected by that state's voters for a six-year term. The House of Representatives has 435 voting members, elected for a two-year term by the constituency of the congressional district in which they reside. District boundaries are generally drawn by state legislatures or redistricting commissions under state law. Every U.S. congressional district must be as nearly equal in population as practicable; each sends one representative to Congress. Election years for senators are staggered so that only one-third of them will be up for election every two years. U.S. representatives are all up for election at the same time every two years. The U.S. Congress makes federal law, declares war, has the power of the purse, and has the power of impeachment. The Senate gives advice and consent to the ratification of treaties by a two-thirds vote of senators present. One of the foremost non-legislative functions of Congress is the power to investigate and oversee the executive branch. Congressional oversight is usually delegated to committees and is facilitated by Congress' power to issue subpoenas. Much of the work of Congress is performed by a collection of committees, each appointed for a specific purpose or function. Committee membership is by tradition and statute bipartisan, but all committees are chaired by a member of the majority party, who sets the committee agenda.
=== Poisoning of Emilian Gebrev === In the aftermath of the Skripal poisoning, investigative journalists were able to track some of the people involved also in Bulgaria. This is how another suspected poisoning case dating back to April 2015 during their stay in the country was linked to the Novichok nerve agent. The victim was the Bulgarian arms dealer Emilian Gebrev, who shared two hypotheses why he might have been attacked: The first one links to the fact that his arms manufacturing company Dunarit exports defense equipment to Ukraine. The other one relates to an attempt by an offshore company to take over Dunarit. The takeover attempt was ultimately linked to the influential Bulgarian politician and oligarch Delyan Peevski who has historically been funded by Russia's state-owned VTB Bank. In November 2023 Bulgaria sought the extradition of three Russian GRU officers, Sergey Fedotov, Georgi Gorshkov and Sergey Pavlov, suspected of the poisoning incident. Sergei Fedotov was also the alias used by one of the assassins in the Salisbury poisonings.
direct zoonotic transmission to humans (spillover), assessed as "possible to likely" introduction through an intermediate host followed by a spillover, assessed as "likely to very likely" introduction through the (cold) food chain, assessed as "possible" introduction through a laboratory incident, assessed as "extremely unlikely" The report mentions that direct zoonotic transmission to humans has a precedent, as most current human coronaviruses originated in animals. Zoonotic transmission is also supported by the fact that RaTG13 binds to hACE2, although the fit is not optimal. The investigative team noted the requirement for further studies, noting that these would "potentially increase knowledge and understanding globally."
DiCaprio is regarded as one of the finest actors of his generation. In a 2022 readers' poll by Empire, he was voted one of the 50 greatest actors of all time. The magazine praised his willingness to "go to the ends of the earth (often literally) to get under his characters' skin". Colin Covert of The Seattle Times similarly believed DiCaprio "redefines film stardom" through his willingness to take on challenging roles that few of his contemporaries are capable of performing. Since his international stardom with Titanic (1997), he has admitted feeling nervous about starring in big-budget studio films because of their hype and marketing campaigns. As an actor, he views film as a "relevant art form, like a painting or sculpture. A hundred years from now, people will still be watching that movie." He often plays roles based on real-life people and stories told in specific periods. According to Caryn James, DiCaprio is unafraid of working with established directors on unconventional projects; taking such risks has led him to star in failed films like The Beach (2000), but also his successful collaborations with Martin Scorsese. DiCaprio has described his relationship with Scorsese as dreamlike and admires his knowledge of film, crediting the director with having taught him its history and importance. Scorsese has commented on DiCaprio's ability to repeatedly demonstrate emotion on screen. Jesse Hassenger of The A.V.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.